Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy

Kang Yan110 enrolled

Overview

The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.

Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Sepsis

Interventions

no interventionsOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical symptoms of sepsis, severe sepsis and septic shock * age over 18 years Exclusion Criteria: * preexisting Neurological diseases * traumatic brain injury * intracranial infectious disease * severe hepatic or renal dysfunction * ICU discharge Within 72 hours * pregnancy

Locations (1)

Kang Yan

Chengdu, Sichuan, China

Outcomes

Primary Outcomes

relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy

To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).

Time frame: cerebral perfusion pressure is assessed up to 72 hours

Secondary Outcomes

Duration of mechanical ventilation

Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months

Time of ICU stay

Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months

Time of hospital stay

Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months

90-day mortality rate

Time frame: All the participants will be followed up until 90 days after their enrollment or death

1-year mortality rate

Time frame: All the participants will be followed up until 1 year after their enrollment or death

2-year mortality rate

Time frame: All the participants will be followed up until 2 years after their enrollment or death

1-year quality of life of survivors

EQ-5D will be used to evaluate quality of life of survivors

Time frame: All the participants will be followed up until 1 year after their enrollment or death

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.